Evaluating cross-reactivity of new psychoactive substances (NPS) in human whole blood by enzyme-linked immunosorbent assay (ELISA)
Journal of Analytical Toxicology · 2024
DOI: 10.1093/jat/bkae017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Analytical Toxicology, 2024. Verfasst von Grace Cieri und 3 weiteren Autor:innen. Beteiligte Einrichtung: Center for Forensic Science Research and Education, 206 Welsh Road, Horsham, PA 19044, USA. Hauptthemen laut MEDLINE: Hallucinogens, Central Nervous System Stimulants. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 17 Literaturangaben. Gefördert von: National Institute of Justice.
Abstract (Originalsprache)
Due to the increase in the use of novel psychoactive substances (NPS) and their overall prevalence, it is important to have effective and reliable screening technologies to detect NPS in biological matrices. Enzyme-linked immunosorbent assays (ELISA) are among the most popular screening methods. To evaluate the effectiveness of ELISA for NPS detection, five subclasses of NPS (novel synthetic opioids, fentanyl analogs, stimulants, benzodiazepines and hallucinogens) were evaluated in whole blood for their cross-reactivity on commercially available ELISA kits. A variety of novel synthetic opioids were tested at concentrations of 1–80 ng/mL and 50–2000 ng/mL and demonstrated no cross-reactivity to a morphine ELISA plate at either concentration range. Fentanyl analogs were tested at concentrations ranging from 0.01 to 1 ng/mL and had cross-reactivities ranging from 8% to 178% on the fentanyl ELISA kit used. Both para-chloro fentanyl (178%) and acryl fentanyl (164%) showed cross-reactivities well above that of fentanyl. Novel stimulants were tested at concentrations of 0.5–40 ng/mL and 20–2,000 ng/mL. 4-Fluoroamphetamine was the only novel stimulant with cross-reactivity (3,354%) to the amphetamine ELISA plate. Novel benzodiazepines were tested at concentrations of 1–40 ng/mL on a benzodiazepine plate. Cross-reactivities ranged from 36.1% to 263%, with desalkylflurazepam having the highest cross-reactivity. Finally, novel hallucinogens were tested at concentrations of 0.5–10 ng/mL on a phencyclidine (PCP) ELISA plate, which produced no cross-reactivity and then with 10–1,000 ng/mL, which gave results from 56.6% to 151%. Both hydroxy-PCP (151%) and chloro-PCP (137%) showed cross-reactivities above that of PCP. This research has demonstrated the utility of using ELISA-based screening for novel benzodiazepines, hallucinogens and for fentanyl analogs; however, there is limited application and risk of false-negative results for the other drug classes due to low or non-existent cross-reactivities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Forensic Science Research and Education, 206 Welsh Road, Horsham, PA 19044, USA.
- NMS Labs, 200 Welsh Road, Horsham, PA 19044, USA.
ORCID-Profile: Grace Cieri, Amanda L A Mohr, Barry K Logan
Förderung
- National Institute of Justice
Zitieren
APA
Cieri, G., Mohr, A. L. A., Mastrovito, R., & Logan, B. K. (2024). Evaluating cross-reactivity of new psychoactive substances (NPS) in human whole blood by enzyme-linked immunosorbent assay (ELISA). Journal of Analytical Toxicology. https://doi.org/10.1093/jat/bkae017
Vancouver
Cieri G, Mohr ALA, Mastrovito R, Logan BK. Evaluating cross-reactivity of new psychoactive substances (NPS) in human whole blood by enzyme-linked immunosorbent assay (ELISA). Journal of Analytical Toxicology. 2024. doi:10.1093/jat/bkae017
BibTeX
@article{Cieri2024,
author = {Cieri, Grace and Mohr, Amanda L A and Mastrovito, Rebecca and Logan, Barry K},
title = {Evaluating cross-reactivity of new psychoactive substances (NPS) in human whole blood by enzyme-linked immunosorbent assay (ELISA)},
journal = {Journal of Analytical Toxicology},
year = {2024},
doi = {10.1093/jat/bkae017}
}
EUVIMED